A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder
Wink LK, Adams R, Wang Z, Klaunig JE, Plawecki MH, Posey DJ, McDougle CJ, Erickson CA
Published in Molecular Autism
Key Findings
NAC up to 60 mg/kg/d for 12 weeks was well tolerated and raised plasma glutathione-related markers but produced no significant improvement in social impairment versus placebo.
Conclusions
Oral NAC increases glutathione biomarkers without clear behavioural benefit in this pilot.
Limitations
Pilot sample (n=31), short duration, exploratory biomarkers.
Supplements Studied
A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder
NAC up to 60 mg/kg/d for 12 weeks was well tolerated and raised plasma glutathione-related markers but produced no significant improvement in social impairment versus placebo.
Outcomes Measured
A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.